title: Phenotypic changes of leukemic cells in a patient with prolympho-plasmacytic leukaemia after treatment with fludarabine.
authors.affiliation: Dipartimento di Clinica Medica, Immunologia e Malattie Infettive, Università degli Studi di Bari.
authors.forename: M P
authors.initials: MP
authors.lastname: Loria
authors.forename: A
authors.initials: A
authors.lastname: Dell'Osso
authors.forename: M
authors.initials: M
authors.lastname: Grande
authors.forename: P
authors.initials: P
authors.lastname: Dambra
authors.forename: L
authors.initials: L
authors.lastname: D'Oronzio
authors.forename: R
authors.initials: R
authors.lastname: Crollo
authors.forename: E
authors.initials: E
authors.lastname: Lasaracina
authors.forename: G
authors.initials: G
authors.lastname: Lucivero
mesh_terms: D000368:Aged; D015703:Antigens, CD / Q000276:immunology; D000970:Antineoplastic Agents / Q000627:therapeutic use; D006801:Humans; D016130:Immunophenotyping; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007952:Leukemia, Plasma Cell / Q000276:immunology* / Q000473:pathology*; D015463:Leukemia, Prolymphocytic / Q000276:immunology* / Q000473:pathology*; D008214:Lymphocytes / Q000276:immunology; D008297:Male; D010641:Phenotype; D014740:Vidarabine / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D015703:Antigens, CD; D000970:Antineoplastic Agents; D007166:Immunosuppressive Agents; D014740:Vidarabine; C024352:fludarabine